Drug Profile
BMS 180431
Alternative Names: BMS180431; BMY 21950; BMY 22566Latest Information Update: 27 Aug 2015
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antihyperlipidaemics
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 22 Dec 2010 Phase-II clinical trials in Hyperlipidaemia in USA (unspecified route)
- 01 Jun 1999 No-Development-Reported for Hyperlipidaemia in USA (Unknown route)